Credit Suisse 2010 Healthcare Conference | |
Wednesday, November 10, at 4:30 p.m. ET / 2:30 p.m. MT in Phoenix | |
Lazard Capital Markets 7th Annual Healthcare Conference | |
Tuesday, November 16, at 9:55 a.m. ET in New York | |
A live webcast of each event will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com. A replay also will be available within 24 hours for seven days following the presentation.
About MAP Pharmaceuticals
MAP Pharmaceuticals is an emerging biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX orally inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of its Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.
Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.
CONTACTS: | |
Nicole Foderaro | |
WCG | |
(415) 946-1058 | |
nfoderaro@wcgworld.com | |
SOURCE MAP Pharmaceuticals, Inc.
